Thursday, June 27, 2013 9:12:17 PM
Let me see if I can do this like one of our favorite posters does...
The government will not fund the trials---there are no government grants in place. The company or a BP will fund. This is why trials are so lengthy for smaller companies THE COSTS ARE EXTREME.------- (insert a goofy smiley face here).
Hemaxellerate is a derivative---the possible offshoots from the source of Hemaxellerate is far reaching (now I will let you figure out what that means) and lands safely in the center of an 18 billion dollar market that is just a fraction of the overall market.------ (Insert goofy smiley face here, too).
Trials do NOT have to take place here in the U.S. (and whether or not Regen intends to conduct trials here, we still do not know for certain). Trials can easily be conducted in some place with a much higher % of AA patients. Someplace like, oh, I dunno, ASIA, where the private health care plans are very limited compared to that of the U.S. and where people line up for clinical trials like a crackhead at a methadone clinic (no offense to the Chinese).----- (insert yet another goofy smiley face here)
There are several large BP companies who have implemented major changes to their regenerative med divisions, working closely with international governments to conduct trials. Funding smaller biotech companies who have worked years to establish credibility in the circles who have shown reasonable amounts of productivity in this sector are ALWAYS in their best interest. It saves them lots of cash (even with multi hundred million dollar acquisitions though an acquisition is not on the table with Regen) and time funding trials when such trials conducted by a smaller biotech.------ (insert that goofy smiley face I have been mentioning again)
But, since you are a bio guru, you probably already knew all this, eh? Or not.
I STRONGLY encourage you to read and reread paragraph two of the above.
The government will not fund the trials---there are no government grants in place. The company or a BP will fund. This is why trials are so lengthy for smaller companies THE COSTS ARE EXTREME.------- (insert a goofy smiley face here).
Hemaxellerate is a derivative---the possible offshoots from the source of Hemaxellerate is far reaching (now I will let you figure out what that means) and lands safely in the center of an 18 billion dollar market that is just a fraction of the overall market.------ (Insert goofy smiley face here, too).
Trials do NOT have to take place here in the U.S. (and whether or not Regen intends to conduct trials here, we still do not know for certain). Trials can easily be conducted in some place with a much higher % of AA patients. Someplace like, oh, I dunno, ASIA, where the private health care plans are very limited compared to that of the U.S. and where people line up for clinical trials like a crackhead at a methadone clinic (no offense to the Chinese).----- (insert yet another goofy smiley face here)
There are several large BP companies who have implemented major changes to their regenerative med divisions, working closely with international governments to conduct trials. Funding smaller biotech companies who have worked years to establish credibility in the circles who have shown reasonable amounts of productivity in this sector are ALWAYS in their best interest. It saves them lots of cash (even with multi hundred million dollar acquisitions though an acquisition is not on the table with Regen) and time funding trials when such trials conducted by a smaller biotech.------ (insert that goofy smiley face I have been mentioning again)
But, since you are a bio guru, you probably already knew all this, eh? Or not.
I STRONGLY encourage you to read and reread paragraph two of the above.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
